Search research articles
Contact Us
Filters
Showing results (1-10 of 170) with videos related to
Page
of 17
Sort By:
Therapeutic Advances in Medical Oncology
|
July 27, 2011
Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists
Jorge A Garcia
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2006
Systemic chemotherapy for advanced bladder cancer: update and controversies
Jorge A Garcia, Robert Dreicer
Molecular Cancer Therapeutics
|
June 21, 2008
Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies
Jorge A Garcia, David Danielpour
Nature Clinical Practice. Urology
|
February 14, 2006
Adjuvant and neoadjuvant chemotherapy for bladder cancer: management and controversies
Jorge A Garcia, Robert Dreicer
Current Opinion in Urology
|
March 26, 2009
Complications of androgen deprivation therapy in prostate cancer
Anita Schwandt, Jorge A Garcia
Oncology (Williston Park, N.Y.)
|
May 10, 2011
Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm
Jorge A Garcia, Robert Dreicer
Current Oncology Reports
|
January 19, 2011
Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer
Mohamed Salem, Jorge A Garcia
Current Opinion in Urology
|
April 5, 2012
Novel agents for the management of castration-resistant prostate cancer
Housam Haddad, Jorge A Garcia
Current Oncology Reports
|
February 2, 2013
Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor
Hui Zhu, Jorge A Garcia
Journal of Carcinogenesis
|
May 7, 2014
Novel agents in the management of castration resistant prostate cancer
Shruti Chaturvedi, Jorge A Garcia
Page
of 17
Search research articles
Search
Showing results (1-10 of 170) with videos related to
Sort By:
Page
of 17
Therapeutic Advances in Medical Oncology
|
July 27, 2011
Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists
Jorge A Garcia
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2006
Systemic chemotherapy for advanced bladder cancer: update and controversies
Jorge A Garcia, Robert Dreicer
Molecular Cancer Therapeutics
|
June 21, 2008
Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies
Jorge A Garcia, David Danielpour
Nature Clinical Practice. Urology
|
February 14, 2006
Adjuvant and neoadjuvant chemotherapy for bladder cancer: management and controversies
Jorge A Garcia, Robert Dreicer
Current Opinion in Urology
|
March 26, 2009
Complications of androgen deprivation therapy in prostate cancer
Anita Schwandt, Jorge A Garcia
Oncology (Williston Park, N.Y.)
|
May 10, 2011
Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm
Jorge A Garcia, Robert Dreicer
Current Oncology Reports
|
January 19, 2011
Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer
Mohamed Salem, Jorge A Garcia
Current Opinion in Urology
|
April 5, 2012
Novel agents for the management of castration-resistant prostate cancer
Housam Haddad, Jorge A Garcia
Current Oncology Reports
|
February 2, 2013
Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor
Hui Zhu, Jorge A Garcia
Journal of Carcinogenesis
|
May 7, 2014
Novel agents in the management of castration resistant prostate cancer
Shruti Chaturvedi, Jorge A Garcia
Page
of 17